194 related articles for article (PubMed ID: 31992715)
1. HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors.
Song KH; Oh SJ; Kim S; Cho H; Lee HJ; Song JS; Chung JY; Cho E; Lee J; Jeon S; Yee C; Lee KM; Hewitt SM; Kim JH; Woo SR; Kim TW
Nat Commun; 2020 Jan; 11(1):562. PubMed ID: 31992715
[TBL] [Abstract][Full Text] [Related]
2. Nanog signaling in cancer promotes stem-like phenotype and immune evasion.
Noh KH; Kim BW; Song KH; Cho H; Lee YH; Kim JH; Chung JY; Kim JH; Hewitt SM; Seong SY; Mao CP; Wu TC; Kim TW
J Clin Invest; 2012 Nov; 122(11):4077-93. PubMed ID: 23093782
[TBL] [Abstract][Full Text] [Related]
3. LC3B upregulation by NANOG promotes immune resistance and stem-like property through hyperactivation of EGFR signaling in immune-refractory tumor cells.
Kim S; Cho H; Hong SO; Oh SJ; Lee HJ; Cho E; Woo SR; Song JS; Chung JY; Son SW; Yoon SM; Jeon YM; Jeon S; Yee C; Lee KM; Hewitt SM; Kim JH; Song KH; Kim TW
Autophagy; 2021 Aug; 17(8):1978-1997. PubMed ID: 32762616
[TBL] [Abstract][Full Text] [Related]
4. Stabilization of HDAC1 via TCL1-pAKT-CHFR axis is a key element for NANOG-mediated multi-resistance and stem-like phenotype in immune-edited tumor cells.
Woo SR; Lee HJ; Oh SJ; Kim S; Park SH; Lee J; Song KH; Kim TW
Biochem Biophys Res Commun; 2018 Sep; 503(3):1812-1818. PubMed ID: 30060952
[TBL] [Abstract][Full Text] [Related]
5. HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells.
Song KH; Choi CH; Lee HJ; Oh SJ; Woo SR; Hong SO; Noh KH; Cho H; Chung EJ; Kim JH; Chung JY; Hewitt SM; Baek S; Lee KM; Yee C; Son M; Mao CP; Wu TC; Kim TW
Cancer Res; 2017 Sep; 77(18):5039-5053. PubMed ID: 28716899
[TBL] [Abstract][Full Text] [Related]
6. NANOG signaling promotes metastatic capability of immunoedited tumor cells.
Lee HJ; Noh KH; Lee YH; Song KH; Oh SJ; Kim SY; Kim TW
Clin Exp Metastasis; 2015 Jun; 32(5):429-39. PubMed ID: 25899063
[TBL] [Abstract][Full Text] [Related]
7. Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle.
Oh SJ; Lee HJ; Song KH; Kim S; Cho E; Lee J; Bosenberg MW; Kim TW
J Clin Invest; 2022 Mar; 132(6):. PubMed ID: 35104240
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation.
Almozyan S; Colak D; Mansour F; Alaiya A; Al-Harazi O; Qattan A; Al-Mohanna F; Al-Alwan M; Ghebeh H
Int J Cancer; 2017 Oct; 141(7):1402-1412. PubMed ID: 28614911
[TBL] [Abstract][Full Text] [Related]
9. Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma.
Steinmann S; Gali-Muhtasib H; Huebner K; Al-Halabi R; Abou Merhi R; Aman P; Agaimy A; Haller F; Schneider-Stock R
Cancer Lett; 2015 Oct; 367(2):147-56. PubMed ID: 26225840
[TBL] [Abstract][Full Text] [Related]
10. Two-stage induced differentiation of OCT4+/Nanog+ stem-like cells in lung adenocarcinoma.
Li R; Huang J; Ma M; Lou Y; Zhang Y; Wu L; Chang DW; Zhao P; Dong Q; Wu X; Han B
Oncotarget; 2016 Oct; 7(42):68360-68370. PubMed ID: 27588392
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic inhibition of AKT leads to cell death in relapsed multiple myeloma.
Song IS; Jeong YJ; Jeong SH; Kim HK; Ha NC; Shin M; Ko KS; Rhee BD; Shim S; Jang SW; Han J
Cancer Lett; 2018 Sep; 432():205-215. PubMed ID: 29933047
[TBL] [Abstract][Full Text] [Related]
12. HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells.
Park KS; Hong YS; Choi J; Yoon S; Kang J; Kim D; Lee KP; Im HS; Lee CH; Seo S; Kim SW; Lee DH; Park SR
BMB Rep; 2018 Dec; 51(12):660-665. PubMed ID: 30591093
[TBL] [Abstract][Full Text] [Related]
13. Androgen/androgen receptor axis maintains and promotes cancer cell stemness through direct activation of Nanog transcription in hepatocellular carcinoma.
Jiang L; Shan J; Shen J; Wang Y; Yan P; Liu L; Zhao W; Xu Y; Zhu W; Su L; Chen J; Cheng F; Yao H; Xu H; Qian C; Liang Z
Oncotarget; 2016 Jun; 7(24):36814-36828. PubMed ID: 27167111
[TBL] [Abstract][Full Text] [Related]
14. Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype.
Noh KH; Lee YH; Jeon JH; Kang TH; Mao CP; Wu TC; Kim TW
Cancer Res; 2012 Apr; 72(7):1717-27. PubMed ID: 22337995
[TBL] [Abstract][Full Text] [Related]
15. Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis.
Oh SJ; Lee J; Kim Y; Song KH; Cho E; Kim M; Jung H; Kim TW
Immune Netw; 2020 Feb; 20(1):e7. PubMed ID: 32158595
[TBL] [Abstract][Full Text] [Related]
16. NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59.
Son SW; Cho E; Cho H; Woo SR; Lee HJ; Oh SJ; Kim S; Kim JH; Chung EJ; Chung JY; Kim MG; Song KH; Kim TW
Sci Rep; 2022 May; 12(1):8652. PubMed ID: 35606403
[TBL] [Abstract][Full Text] [Related]
17. C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway.
Ching RHH; Sze KMF; Lau EYT; Chiu YT; Lee JMF; Ng IOL; Lee TKW
Oncotarget; 2017 Apr; 8(14):23507-23516. PubMed ID: 28186991
[TBL] [Abstract][Full Text] [Related]
18. Reduction of NANOG Mediates the Inhibitory Effect of Aspirin on Tumor Growth and Stemness in Colorectal Cancer.
Wang H; Liu B; Wang J; Li J; Gong Y; Li S; Wang C; Cui B; Xue X; Yang M; Fan W; Kang Z; Kamran M; Xu J; Tian P; Luo Y; Hou Z; Dong L; Ren Y; Li M; Wen Q; Cheng W; Xu L; Wang L; Liu Q
Cell Physiol Biochem; 2017; 44(3):1051-1063. PubMed ID: 29179207
[TBL] [Abstract][Full Text] [Related]
19. Cutting edge: Hypoxia-induced Nanog favors the intratumoral infiltration of regulatory T cells and macrophages via direct regulation of TGF-β1.
Hasmim M; Noman MZ; Messai Y; Bordereaux D; Gros G; Baud V; Chouaib S
J Immunol; 2013 Dec; 191(12):5802-6. PubMed ID: 24227785
[TBL] [Abstract][Full Text] [Related]
20. RACK1 Promotes Self-Renewal and Chemoresistance of Cancer Stem Cells in Human Hepatocellular Carcinoma through Stabilizing Nanog.
Cao J; Zhao M; Liu J; Zhang X; Pei Y; Wang J; Yang X; Shen B; Zhang J
Theranostics; 2019; 9(3):811-828. PubMed ID: 30809310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
